Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hodgkin Disease × avelumab × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 3 Lymphoma, Follicular 2 Sezary Syndrome 1 Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, T-Cell 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell 1 Hodgkin Disease 1 Central Nervous System Neoplasms 1 Carcinoma, Neuroendocrine 1 Cancer That is Associated With a Chronic Viral Infection 1

Interventions

Cyclophosphamide 179 fludarabine phosphate 107 Etoposide 100 Peripheral Blood Stem Cell Transplantation 91 Filgrastim 83 Mycophenolic Acid 81 Doxorubicin 78 Whole-Body Irradiation 74 Melphalan 73 Brentuximab Vedotin 70 Radiotherapy 69 Tacrolimus 67 fludarabine 64 Busulfan 64 Vinblastine 59 Cyclosporine 58 Rituximab 56 Dacarbazine 49 Gemcitabine 48 Granulocyte Colony-Stimulating Factor 47 Bleomycin 47 Vincristine 43 Antilymphocyte Serum 43 Prednisone 41 Cytarabine 41 Nivolumab 40 Methotrexate 39 Carmustine 34 pembrolizumab 31 Sirolimus 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03617666 2023-12-12

AVENuE

University College, London

Phase 2 Unknown

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡